{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03887208",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2ABC Therapy"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2016-004110-10",
            "SecondaryIdType": "EudraCT Number"
          },
          {
            "SecondaryId": "267976/13/NCBR/2015",
            "SecondaryIdType": "Other Grant/Funding Number",
            "SecondaryIdDomain": "The National Center for Research and Development, Poland"
          },
          {
            "SecondaryId": "PL008125",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "EU tissue establishment code"
          },
          {
            "SecondaryId": "Z4217",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "ISBT128 (Facility Identification Number)"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Medical University of Warsaw",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells",
      "OfficialTitle": "Evaluation the Safety and Efficacy of the Treatment of Scars and Cutis Laxa Syndrome With the Use of Autologous (Fresh and Stored) Stem Cells Isolated From Adipose Tissue.",
      "Acronym": "2ABC"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 31, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 31, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 31, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "October 30, 2018",
      "StudyFirstSubmitQCDate": "March 20, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 22, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 27, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 28, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Medical University of Warsaw",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Timeless Chirurgia Plastyczna-Janusz Jaworowski",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Melitus sp. z o.o.",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Polish Stem Cells Bank S.A.",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The aim of this study is to compare clinical outcomes of patients with large scars or Cutis laxa treated with injections of autologous stromal vascular fraction cells (SVF) and adipose-derived mesenchymal stem cells (ADSC).",
      "DetailedDescription": "Patients suffering from cutis laxa senilis and scars (atrophic, hypertrophic, developed due to surgery, trauma, diseases such as acne vulgaris, post-burn scars) will be treated with product containing - human autologous stromal vascular fraction (SVF) cells and human autologous adipose-derived mesenchymal stem cells (ADSC)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Skin",
          "Scar",
          "Cutis Laxa",
          "Keloid",
          "Cicatrix"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "scar treatment",
          "cutis laxa treatment",
          "stromal vascular fraction",
          "adipose-derived mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Patients receive injections of autologous SVF or ADSC cells isolated in the laboratory from adipose tissue.",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "100",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous adipose derived stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous ADSC injection combined with laser therapy of the skin.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Laser therapy",
                "Biological: Autologous ADSC injection"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo - Normal saline injection",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Normal sline injection combined with laser therapy of the skin.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Laser therapy",
                "Procedure: Normal saline injection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "Laser therapy",
            "InterventionDescription": "non-ablative fractional laser therapy of skin",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous adipose derived stem cells",
                "Placebo - Normal saline injection"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous ADSC injection",
            "InterventionDescription": "Subcutaneous injection of autologous ADSC",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous adipose derived stem cells"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Normal saline injection",
            "InterventionDescription": "Subcutaneous Normal saline injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo - Normal saline injection"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in patient's skin condition",
            "PrimaryOutcomeDescription": "Evaluation of the effectiveness of the method of application of stem cells in the described indications by evaluating the time after which there will be an improvement of 50% in the point evaluation scale of the quality of life of the patient in relation to the baseline values.\n\nScale 1: Impact of skin problems on the quality of life. The aim is to assess to what extent skin ailments have affected the patient's life in the last 2 weeks.\n\nA five-level scale of evaluation (from 'very strong' to 'not applicable') .The \"very strong\" value means the worst result, while the \"not applicable\" value is the best result.",
            "PrimaryOutcomeTimeFrame": "0-27 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Evaluation of skin problems. Assessment of skin related complaints since the last visit.",
            "PrimaryOutcomeDescription": "Scale 2: A seven-level grading scale (from \"0\" to \"6\").The value \"0\" means the best result, while \"6\" is the worst result.",
            "PrimaryOutcomeTimeFrame": "0-27 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "The assessment of the scar by the patient.",
            "PrimaryOutcomeDescription": "Scale 3: Six-point scale (from '1' to '6'). The value \"1\" means the best result, while \"6\" is the worst result.",
            "PrimaryOutcomeTimeFrame": "0-27 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in volume of the skin (USG)",
            "SecondaryOutcomeDescription": "Changes in the volume of the fat layer at the application site assessed by skin (USG) thickness.",
            "SecondaryOutcomeTimeFrame": "0-27 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in skin surface morphology (digital imagining)",
            "SecondaryOutcomeDescription": "Changes in skin surface morphology assessed by digital imaging.",
            "SecondaryOutcomeTimeFrame": "0-27 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Record of adverse events",
            "SecondaryOutcomeDescription": "Evaluation of safety of the method of cells' application assessed by adverse events",
            "SecondaryOutcomeTimeFrame": "0-27 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18 - 75 years at the time of qualification to the study\nSigning informed consent form\nWomen / men\n\nScar or cutis laxa\n\nScar eligibility conditions:\n\nArea:\n\nStomach\nLimbs\nFace\nBack\n\nChest and neck\n\nOnset time: over 6 months\nScars previously untreated\nAtrophic and hypertrophic scars\nTwo scars in close location, each from 2 to 6 cm long and a total surface area of 1 sq. cm to 5 sq. cm or single scar\n\nEtiology\n\ntraumatic\nburns\nsurgical\n\nCutis laxa eligibility conditions:\n\nSun discoloration\nPigmentation changes\nSolar stains\nPigment changes also called age spots.\nErythema\nCracked blood vessels\nRuby nevus\nAtrophic changes of the skin and subcutaneous tissue\nChanges symmetrically present on both hands\nWithout previous aesthetic treatment in this area, previous standard care.\nPatient's health which allows anesthesia for liposuction.\nReady for follow-up visits\n\nExclusion Criteria:\n\nActive cancer (diagnosed during past 5 years), excluding cured nonmelanoma skin cancer or other non-invasive or in situ cancer (eg. cervical cancer)\nActive chronic infection\nChronic use of NSAIDs\nTaking any anticoagulant by the patient during 1 hour prior to surgery (excluding prophylactic heparin before liposuction).\nCoagulation disorders in medical history and actual test results out of normal ranges.\nSkin infections.\nAllergies to medications used during liposuction (eg. Lidocaine and derivatives).\nStatus post radiotherapy or chemotherapy\nAny other disease or condition that may change the evaluation of skin condition (eg. autoimmune disease of the connective tissue)\nTaking the corticosteroid drugs or cytotoxic medications during the past 30 days\nAllergy to materials of animal origin\nDiagnosis of diabetes Type I\nDiagnosis of AIDS, hepatitis B virus (HBV) or hepatitis C virus (HCV) (positive laboratory test result)\nHirsutism or a tattoo at the treatment site\nInsufficient fat tissue for fat donation\nScar after removal of cancer.\nThe patient does not qualify to participate in this study in the opinion of the investigator\nPregnancy, breast feeding.\nPhotoallergy or using the drugs causing photoallergy.\nActive herpes\nIdiopathic keloids\nEsthetic or medicinal treatments done previously at the treatment site\nThe use of derivatives of vitamin A during 6 months before the treatment\nFitzpatrick phototype V and VI\nPatients with mental disorders or addicted to drugs and/or alcohol.\nParticipation in other clinical study during the past 6 months.\n\nReactive result of serological and viral tests (ie. HIV-1 and 2 (HIV Ag/ Ab)\n\nHepatitis B Virus Infection, - HbsAg and Anti-hepatitis B core antigen (Anti-HBc);\nHepatitis C Virus Infection, Anti-HCV;\nSyphilis specific tests",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Maria Noszczyk-Kostrzewa, PhD",
            "OverallOfficialAffiliation": "Melitus Ltd",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Janusz R Jaworowski, PhD",
            "OverallOfficialAffiliation": "Timeless Ltd",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Laboratory for Cell Research and Application, Medical University of Warsaw",
            "LocationCity": "Warsaw",
            "LocationCountry": "Poland"
          },
          {
            "LocationFacility": "Melitus sp. z o.o.",
            "LocationCity": "Warsaw",
            "LocationCountry": "Poland"
          },
          {
            "LocationFacility": "Timeless Chirurgia Plastyczna Sp. z o. o.",
            "LocationCity": "Warsaw",
            "LocationCountry": "Poland"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003483",
            "ConditionMeshTerm": "Cutis Laxa"
          },
          {
            "ConditionMeshId": "D000002921",
            "ConditionMeshTerm": "Cicatrix"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000005355",
            "ConditionAncestorTerm": "Fibrosis"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000012873",
            "ConditionAncestorTerm": "Skin Diseases, Genetic"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5312",
            "ConditionBrowseLeafName": "Cicatrix",
            "ConditionBrowseLeafAsFound": "Cicatrix",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9806",
            "ConditionBrowseLeafName": "Keloid",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5844",
            "ConditionBrowseLeafName": "Cutis Laxa",
            "ConditionBrowseLeafAsFound": "Cutis Laxa",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14828",
            "ConditionBrowseLeafName": "Skin Diseases, Genetic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T1692",
            "ConditionBrowseLeafName": "Cutis Laxa",
            "ConditionBrowseLeafAsFound": "Cutis Laxa",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}